Get the Stockscreener App
5.49
1.96%
-0.11
Abeona Therapeutics Inc stock is traded at $5.49, with a volume of 1.52M.
It is down -1.96% in the last 24 hours and up +1.67% over the past month.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.
See More
Previous Close:
$5.60
Open:
$5.6
24h Volume:
1.52M
Relative Volume:
1.25
Market Cap:
$312.90M
Revenue:
$5.82M
Net Income/Loss:
$71.18M
P/E Ratio:
5.5054
EPS:
0.9972
Net Cash Flow:
$-84.30M
1W Performance:
-6.95%
1M Performance:
+1.67%
6M Performance:
+23.37%
1Y Performance:
-5.18%
1-Day Range:
$5.41
$5.68
1-Week Range:
$5.41
$6.015
52-Week Range:
$4.00
$7.5401
Abeona Therapeutics Inc Stock (ABEO) Company Profile
Name
Abeona Therapeutics Inc
Sector
Industry
Phone
646-813-4701
Address
6555 CARNEGIE AVE, 4TH FLOOR, CLEVELAND, NY
Compare ABEO vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABEO
Abeona Therapeutics Inc
|
5.49 | 319.17M | 5.82M | 71.18M | -84.30M | 0.9972 |
VRTX
Vertex Pharmaceuticals Inc
|
436.95 | 114.32B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
698.25 | 74.74B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
799.32 | 51.13B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
286.98 | 39.18B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
145.66 | 31.78B | 742.00K | -1.37B | -1.07B | -7.0731 |
Abeona Therapeutics Inc Stock (ABEO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| Mar-05-25 | Initiated | Oppenheimer | Outperform |
| Jul-03-24 | Initiated | H.C. Wainwright | Buy |
| May-30-24 | Initiated | Stifel | Buy |
| Nov-11-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Sep-18-20 | Initiated | B. Riley FBR | Buy |
| Feb-10-20 | Initiated | SVB Leerink | Outperform |
| Dec-10-19 | Resumed | Cantor Fitzgerald | Neutral |
| Aug-15-19 | Downgrade | Maxim Group | Buy → Hold |
| Aug-12-19 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jul-26-19 | Downgrade | Mizuho | Buy → Neutral |
| Jun-27-19 | Initiated | Mizuho | Buy |
| Oct-12-18 | Initiated | Mizuho | Buy |
| Jun-05-18 | Initiated | Seaport Global Securities | Buy |
| Nov-08-17 | Initiated | SunTrust | Buy |
| Oct-16-17 | Reiterated | H.C. Wainwright | Buy |
| Oct-11-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Oct-10-17 | Initiated | Citigroup | Buy |
| Oct-05-17 | Reiterated | Maxim Group | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Jul-18-17 | Reiterated | Maxim Group | Buy |
| Jun-22-17 | Resumed | Jefferies | Buy |
| Jan-06-17 | Initiated | Jefferies | Buy |
| Sep-29-16 | Reiterated | Maxim Group | Buy |
View All
Abeona Therapeutics Inc Stock (ABEO) Latest News
Abeona (ABEO) director 10b5-1 open-market sale of 26,143 shares - Stock Titan
Nantahala (ABEO) reports 5.78M-share 9.99% stake; managers Harkey, Mack listed - Stock Titan
Nantahala Capital reports 3.33M shares in Abeona (ABEO) as of March 31, 2026 - Stock Titan
ABEO (Nasdaq) Form 144: Insider proposes sale; restricted awards listed - Stock Titan
Jefferies Remains a Buy on Abeona Therapeutics (ABEO) - The Globe and Mail
Abeona Therapeutics Inc. (NASDAQ:ABEO) Q1 2026 Earnings Call Transcript - Insider Monkey
Abeona Therapeutics Q1 2026 Earnings Call: Complete Transcript - Sahm
Abeona Therapeutics Inc (ABEO) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic Expansions - GuruFocus
Abeona Therapeutics Signals Strong Early ZEVASKYN Launch - TipRanks
Abeona Therapeutics Q1 2026 Earnings Call Transcript - MarketBeat
Abeona Therapeutics Q1 2026 earnings preview - MSN
Abeona Therapeutics (ABEO) Reports Strong Q1 Earnings with Reven - GuruFocus
Abeona Therapeutics Q1 Earnings Call Highlights - sharewise.com
Abeona Therapeutics Inc. Q1 2026 Financial Report: Key Highlights, Risk Factors, and ZEVASKYN Commercialization Update - Minichart
Abeona Therapeutics earnings beat by $0.04, revenue topped estimates - Investing.com Canada
Abeona Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
Abeona Therapeutics Q1 2026: Loss Narrows to $0.30/Share - AlphaStreet
Abeona Therapeutics Reports Q1 2026 Results: Strong ZEVASKYN Adoption, Pipeline Focus on PSMA T-Cell Therapy, and $168M Cash Position - Minichart
Earnings call transcript: Abeona Therapeutics Q1 2026 beats expectations with strong revenue - Investing.com
Earnings call transcript: Abeona Therapeutics Q1 2026 beats expectations with strong revenue By Investing.com - Investing.com South Africa
Abeona Therapeutics (ABEO) Reports Strong Q1 Revenue Growth - GuruFocus
ABEO: Q1 revenue surged on ZEVASKYN uptake; profitability targeted by June; pipeline expands to oncology - TradingView
Abeona Reports Strong Q1 Revenue, Expands Treatment Center NetworkAbeona Therapeutics (NASDAQ:ABEO) - Benzinga
Abeona Therapeutics Deprioritizes In-House Ophthalmology Programs >ABEO - Moomoo
Is Abeona Therapeutics (ABEO) Appropriately Valued After a Q1 20 - GuruFocus
Abeona (ABEO) Q1 2026 Earnings Transcript - The Globe and Mail
ABEONA THERAPEUTICS ($ABEO) Releases Q1 2026 Earnings - Quiver Quantitative
ABEONA THERAPEUTICS INC. 1Q 2026: Revenue $8.72M, EPS $(0.30) — 10-Q Summary - TradingView
Abeona Therapeutics posts smaller-than-expected Q1 loss per share - TradingView
Abeona Therapeutics® Reports First Quarter 2026 Results and Provides Pipeline Update - The Manila Times
Abeona Therapeutics (NASDAQ: ABEO) posts Q1 2026 ZEVASKYN sales and $17.1M loss - Stock Titan
Abeona Therapeutics: Q1 Earnings Snapshot - New Castle News
ABEO: ZEVASKYN revenue surged in Q1 2026 as focus shifted to ABO-701 for prostate cancer - TradingView
Abeona Therapeutics reports Q1 2026: $8.7M product revenue, $17.1M net loss - TradingView
ZEVASKYN fuels Abeona (NASDAQ: ABEO) Q1 2026 revenue and pipeline shift - Stock Titan
Abeona pivots to new T-cell therapy aimed at advanced prostate cancer - Stock Titan
Earnings Scheduled For May 13, 2026 - Benzinga
Abeona Therapeutics CCO sells $33,073 in common stock - Investing.com India
Abeona Therapeutics CCO sells $33,073 in common stock By Investing.com - Investing.com Australia
Abeona Therapeutics (ABEO) CCO sells 5,548 shares to cover tax from RSU vesting - Stock Titan
[144] ABEONA THERAPEUTICS INC. SEC Filing - Stock Titan
Abeona Therapeutics Inc expected to post a loss of 36 cents a shareEarnings Preview - TradingView
Abeona activates sixth treatment center for RDEB gene therapy By Investing.com - Investing.com Nigeria
Abeona activates sixth treatment center for RDEB gene therapy - Investing.com
Abeona Therapeutics® Announces Activation of Children's Hospital of Philadelphia as a New Qualified Treatment Center for ZEVASKYN® - The Manila Times
RDEB patients get new Philly hospital option for ZEVASKYN - Stock Titan
Number of shareholders of Abeona Therapeutics Inc. – NASDAQ:ABEO - TradingView
Number of shareholders of Abeona Therapeutics, Inc. – BX:PCJ - TradingView
MSN Money - MSN
(ABEO) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
SEC Form DEFA14A filed by Abeona Therapeutics Inc. - Quantisnow
Abeona Therapeutics Inc Stock (ABEO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):